Table 4.
Multiple regression analysis of preoperative variables with the changes in BCVA between the baseline and 3 months after the initial IVR.
| Variable | r | P value |
|---|---|---|
| Gender | −0.19 | .15 |
| (female = 0, male = 1) | ||
| Smoking | −0.14 | .30 |
| (nonsmoker = 0, present and ever smokers = 1) | ||
| Hypertension | 0.11 | .41 |
| (no history = 0, present = 1) | ||
| Diabetes Mellitus | 0.041 | .76 |
| (no history = 0, present = 1) | ||
| Phenotype | −0.38 | .013 |
| (PCV = 0, tAMD = 1) | ||
| Baseline BCVA (LogMAR) | −0.36 | .026 |
| Baseline CRT (μm) | 0.11 | .40 |
| Subretinal hemorrhage (≦1 DA = 0, >1 DA = 1) | 0.21 | .11 |
| Greatest linear dimension (μm) | 0.15 | .27 |
BCVA: best-corrected visual acuity, IVR: intravitreous ranibizumab, CRT: central retinal thickness, and DA: disc area. r: partial correlation coefficient.